Can Teenagers Take Ozempic? What Parents Actually Need to Know

Roughly 1 in 5 American teenagers between ages 12 and 19 are living with obesity and that’s not a willpower problem, a parenting failure, or a lifestyle choice. It’s a complex chronic disease driven by genetics, hormones, environment, and biology. So when a class of medications starts making headlines for producing the most significant weight loss results medicine has ever seen, parents want answers.

The question is real. The stakes are real. And the answer is more nuanced than a yes or a no.

Here’s the straight story on teenagers and Ozempic what’s FDA approved, what the research says, what the risks are, and what questions every parent should be asking.

First: Ozempic vs. Wegovy The Distinction That Changes Everything

This is the most important clarification to get right, and most headlines skip it entirely.

Ozempic is NOT approved for teenagers. Ozempic (semaglutide at up to 2 mg) is FDA approved for adults 18 and older with type 2 diabetes. Prescribing it to a teenager for weight loss would be off label meaning outside of what the FDA has reviewed and authorized for that age group.

Wegovy IS approved for adolescents aged 12 and older. Wegovy contains the same active ingredient as Ozempic (semaglutide) but at a higher dose (up to 2.4 mg) and with a different FDA indication. In December 2022, the FDA approved Wegovy for chronic weight management in adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex a clinical definition of obesity.

So when a parent asks “can teenagers take Ozempic?”, the more accurate answer is: a teenager cannot take Ozempic for weight loss under FDA approval but they may be eligible for Wegovy if they meet specific medical criteria. If you want to understand the full difference between these two drugs, this breakdown of Ozempic vs. Wegovy covers exactly that.

What Does the Research Actually Show for Teens?

The FDA’s 2022 approval of Wegovy for adolescents was based on the STEP TEENS trial a 68 week, randomized, placebo controlled clinical trial of 201 teenagers ages 12 to 17, all at or above the 95th BMI percentile for their age and sex.

The results were significant:

• The Wegovy group experienced a mean 16.1% reduction in BMI by week 68
• The placebo group had a mean BMI increase of 0.6%
• 73% of teenagers on Wegovy lost at least 5% of their starting body weight
• Participants also saw improvements in cardiometabolic markers blood pressure, blood sugar, and cholesterol

These are meaningful numbers, and they matter for a population where adolescent obesity significantly predicts adult obesity, type 2 diabetes, cardiovascular disease, and reduced quality of life. According to CDC data, the proportion of teenagers with obesity receiving obesity medication prescriptions grew by more than 300% between 2020 and 2023 with Wegovy accounting for 57.1% of those prescriptions in 2023.

The research clearly shows Wegovy can work in adolescents. But “it works” and “it’s the right choice for your teenager” are two very different statements.

The Concerns Parents Need to Hear Honestly

This is where the conversation needs to slow down because the honest picture includes real clinical uncertainties.

Long term effects are unknown. All existing studies on semaglutide in teenagers have run for two years at most. Adolescence is a period of active bone mineralization, growth, hormonal development, and neurological maturation. Researchers have raised specific concerns that caloric restriction driven by appetite suppression could affect bone density, muscle development, and potentially height and pubertal progression though Novo Nordisk’s trial data did not show effects on growth during the trial period. The key phrase is during the trial period. Long term follow up data simply does not exist yet.

Weight rebound when stopping. Studies consistently show that patients who discontinue semaglutide regain significant weight often within months. In teenagers, this raises a critical question: Are we creating a medication dependency starting at age 12 or 13, with no clear long term exit strategy?

Mental health and eating disorder risk. This is the concern most parents haven’t heard about. Clinical experts note that adolescents are especially vulnerable to the psychological effects of appetite suppressing medications. Introducing a drug that dramatically alters hunger and eating patterns during a period when body image, identity formation, and social comparison are already intense can in some cases trigger or worsen disordered eating patterns. This is particularly relevant for any teen with a history of anxiety, depression, trauma, or body image concerns. The Academy for Eating Disorders has specifically flagged adolescents as a high risk group for this complication.

Gastrointestinal side effects hit teens too. Nausea, vomiting, diarrhea, and abdominal discomfort the same GI side effects seen in adults occur in teenagers on Wegovy. During a period where proper nutrition is essential for development, significant GI intolerance is not a minor inconvenience.

Who Might Be an Appropriate Candidate And Who Probably Isn’t

Wegovy for adolescents is not a first line treatment. The FDA’s own label and the American Academy of Pediatrics’ 2023 clinical practice guidelines position it as part of a comprehensive program not a standalone fix.

A teenager might be an appropriate candidate if:

• They are 12 or older with a BMI at or above the 95th percentile for their age and sex (clinical obesity)
• They have obesity related health complications elevated blood sugar, hypertension, high cholesterol, sleep apnea
• They have already participated in structured lifestyle intervention without sufficient results
• They do not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• They have been carefully screened for a personal or family history of eating disorders
• A pediatric obesity specialist or endocrinologist is involved in their care

Wegovy is NOT appropriate for:

• Teenagers who don’t meet the BMI threshold (95th percentile or above)
• Any teen with a history of eating disorders or significant body dysmorphia
• Teenagers who have not first attempted structured lifestyle intervention
• Anyone under 12 the safety data simply does not exist for younger children
• Teens using it for cosmetic or social reasons rather than documented medical need

If you’re wondering whether blood sugar dysregulation or insulin resistance might be part of your teenager’s metabolic picture these are real and important considerations that should be evaluated before any medication conversation.

What Every Parent Should Ask Before Agreeing to This

If a provider suggests Wegovy for your teenager or if you’re considering bringing it up here are the questions that belong in that conversation:

1. Has my child had a comprehensive metabolic and hormonal evaluation? Thyroid dysfunction, insulin resistance, PCOS in girls, and cortisol dysregulation can all drive adolescent weight gain and should be ruled out or treated first. Understanding what a hormone panel actually tests for is a useful starting point.
2. Has my teen completed a structured lifestyle intervention program? Medication should follow not replace documented effort with diet, activity, and behavioral support.
3. Who is monitoring them? Management of Wegovy in teenagers should involve a pediatric specialist, not a general telehealth platform. The clinical complexity here requires experienced oversight.
4. Has anyone screened for eating disorder risk? A mental health assessment should be part of the pre treatment workup for any adolescent.
5. What is the plan if they want to stop? The medication is not intended to be temporary. Parents and teens need an honest conversation about what discontinuation looks like.

Conclusion: The Right Question Isn’t “Can They?” It’s “Should They?”

Teenagers can take Wegovy under FDA approved guidelines if they meet specific criteria. Whether your specific teenager should is a question that requires a thorough evaluation, a qualified specialist, honest family conversation, and a whole person approach not a shortcut born from frustration or social pressure.

Adolescent obesity is real, serious, and deserves real clinical attention. And real clinical attention means looking at the whole picture: hormones, metabolism, nutrition, mental health, and the long term plan not just a prescription.

At AK Twisted Wellness, we serve adults navigating complex metabolic and hormonal health including parents who are trying to understand their own health so they can model and support their families. If you have questions about GLP 1 therapy, metabolic health, or hormonal balance for yourself, our telehealth team is here for real conversations.

Visit aktw.life or call (520) 710 8805.

Frequently Asked Questions

1. Is Ozempic FDA approved for teenagers? No. Ozempic (semaglutide up to 2 mg) is approved only for adults 18 and older with type 2 diabetes. Prescribing it to a teenager for weight loss would be entirely off label. The FDA approved semaglutide option for adolescents is Wegovy, which was approved in December 2022 for teens aged 12 and older with clinical obesity (BMI at or above the 95th percentile for age and sex).

2. How much weight can a teenager lose on Wegovy? The STEP TEENS clinical trial found that adolescents on Wegovy experienced a mean 16.1% BMI reduction over 68 weeks, compared to a 0.6% BMI increase in the placebo group. Seventy three percent of teens on Wegovy lost at least 5% of their starting body weight. These results are similar in magnitude to those seen in adult clinical trials, which is clinically significant.

3. What are the biggest risks of Wegovy for teenagers specifically? The most immediate risks are GI side effects (nausea, vomiting, diarrhea) and the potential for inadequate nutrition during a period of active development. Longer term concerns include unknown effects on bone density, muscle mass, growth, and pubertal development areas where multi year data simply doesn’t yet exist. Mental health risk, including the potential to trigger disordered eating in vulnerable teens, is another serious concern that requires pre treatment screening.

4. What if my teenager doesn’t meet the BMI threshold but I’m still concerned about their weight? Wegovy is only FDA approved for adolescents at or above the 95th BMI percentile. If your teenager doesn’t meet that threshold, the conversation should focus on metabolic health evaluation, nutrition, activity, and mental wellness not medication. A comprehensive evaluation that looks at blood sugar, insulin resistance, thyroid function, and hormones can help identify whether there’s an underlying driver worth addressing.

5. Will a teenager gain the weight back when they stop Wegovy? Research consistently shows that patients adults and adolescents regain significant weight after stopping semaglutide. In the STEP TEENS trial, follow up data showed teens began regaining weight during the off treatment period. This is one of the most challenging realities of GLP 1 therapy at any age, and it’s especially important to have an honest conversation about this with your teenager and their care team before starting.

6. Does AK Twisted Wellness treat teenagers? AK Twisted Wellness serves adults. However, we frequently work with parents who are navigating their own metabolic health, hormonal balance, and weight management and who want to model healthy strategies for their families. If you’re a parent dealing with your own GLP 1 questions, weight loss goals, or hormonal health, our telehealth team provides personalized, whole person care. Visit aktw.life or call (520) 710 8805).

References

1. U.S. Food & Drug Administration / Novo Nordisk. (2022). FDA Approves Novel, Once Weekly Injectable Treatment for Obesity or Overweight in Adolescents Aged 12 Years and Older. https://www.fda.gov/news events/press announcements/fda approves novel once weekly injectable treatment obesity or overweight adolescents aged 12 years
2. Wegovy (semaglutide) Adolescent Prescribing Information. (2025). Novo Nordisk. https://adolescents.wegovy.com
3. Cardiometabolic Health Congress. (2023). FDA Approves Semaglutide for Pediatric Patients. https://www.cardiometabolichealth.org/article/fda approves semaglutide for pediatric patients/
4. Centers for Disease Control and Prevention / MMWR. (2025). Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity United States, 2018–2023. https://www.cdc.gov/mmwr/volumes/74/wr/mm7420a1.htm
5. UCLA Health. (2024). Are GLP 1 Drugs Safe for Children? Doctors Say Despite High Use Among Youth, No Unique Health Risks Detected. https://www.uclahealth.org/news/release/are glp 1 drugs safe children doctors say despite high use
6. Scientific American. (2024). Teenagers Are Taking New Weight Loss Drugs, but the Science Is Far from Settled. https://www.scientificamerican.com/article/the unsettled science behind weight loss drugs for teens/
7. American Academy of Pediatrics. (2023). Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics, 151(2), e2022060640. https://doi.org/10.1542/peds.2022 060640
8. Eating Recovery Center. (2024). Ozempic and Eating Disorders: Risks of GLP 1 Weight Loss Drugs. https://www.eatingrecoverycenter.com/resources/ozempic weight loss drugs side effects
9. DiaTribe. (2023). FDA Approves Weight Loss Drug Wegovy for Teens. https://diatribe.org/diabetes medications/fda approves weight loss drug wegovy teens
10. SingleCare. (2025). Are There Age Restrictions on GLP 1s? https://www.singlecare.com/blog/glp 1 age restrictions/
    

Disclaimer: This content is for informational and educational purposes only and does not constitute medical, legal, or financial advice. Reading this article does not create a patient provider relationship. Medical decisions regarding adolescents and GLP 1 medications should only be made in partnership with a qualified pediatric healthcare provider. If your teenager is experiencing mental health concerns related to weight, body image, or eating, please contact the 988 Suicide & Crisis Lifeline by calling or texting 988. For questions about AK Twisted Wellness services, visit aktw.life or call (520) 710 8805.